Kiniksa Pharmaceuticals, Ltd. (KNSA)

Kiniksa Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	1,311	1,234	1,042	811	1,203	607
Market Cap Growth	85.63%	18.45%	28.46%	-32.59%	98.17%	-56.32%
Enterprise Value	1,110	1,040	857	635	886	376
PE Ratio	153.75	87.60	5.68	-5.13	-7.45	-3.75
PS Ratio	4.35	4.57	4.73	21.04	-	-
PB Ratio	3.04	2.81	2.63	4.38	3.86	2.69
P/FCF Ratio	61.38	93.67	179.80	-6.40	-8.79	-3.76
P/OCF Ratio	60.84	92.76	179.37	-6.42	-8.81	-3.83
EV/Sales Ratio	3.68	3.85	3.89	16.47	-	-
EV/EBITDA Ratio	-72.85	-92.35	52.03	-4.19	-5.81	-2.34
EV/EBIT Ratio	-55.27	-62.43	77.72	-4.05	-5.67	-2.30
EV/FCF Ratio	51.96	78.93	147.92	-5.01	-6.48	-2.33
Debt / Equity Ratio	0.03	0.03	0.01	0.03	0.02	0.01
Debt / EBITDA Ratio	-0.74	-1.09	0.36	-0.04	-0.05	-0.02
Debt / FCF Ratio	0.57	0.93	1.02	-0.05	-0.05	-0.02
Quick Ratio	3.57	3.58	4.32	4.15	10.16	8.39
Current Ratio	4.21	4.34	5.16	4.38	10.46	8.68
Asset Turnover	0.60	0.56	0.65	0.14	0	0
Return on Equity (ROE)	2.10%	3.40%	66.70%	-69.80%	-57.30%	-61.10%
Return on Assets (ROA)	1.70%	2.90%	53.90%	-58.70%	-52.40%	-54.40%
Return on Capital (ROIC)	-6.88%	-5.59%	40.42%	-81.97%	-49.34%	-74.52%
Earnings Yield	0.66%	1.14%	17.60%	-19.48%	-13.42%	-26.67%
FCF Yield	1.63%	1.07%	0.56%	-15.63%	-11.37%	-26.62%
Buyback Yield / Dilution	-1.26%	-2.13%	-2.69%	-10.89%	-14.42%	-82.92%
Total Shareholder Return	-1.26%	-2.13%	-2.69%	-10.89%	-14.42%	-82.92%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).